

COMPANY RESULTS

Indorama Ventures (IVL TB)

4Q18: Weak Profit As Expected But Stronger Outlook

IVL reported net profit of Bt2.4b in 4Q18 (-76% yoy, -77% qoq) and core profit of Bt3.9b (+3% yoy, -53% qoq), in line with our expectations. We still like IVL and expect a strong net profit growth of 12% in 2019 with potential upside from new M&As. We foresee a high probability of consensus raising its 2019 earnings estimate. Maintain BUY and target price of Bt77.00.

4Q18 RESULTS

| Year to 31 Dec (Btm) | 4Q18 | 4Q17 | 3Q18 | yoy % chg | qoq % chg | 2018 | 2017 | yoy % chg |
|-----------------------|---------|---------|---------|-----------|-----------|----------|----------|-----------|
| Revenue | 91,436 | 70,417 | 96,001 | 30 | (5) | 347,171 | 286,332 | 21 |
| Core EBITDA | 10,458 | 8,435 | 13,447 | 24 | (22) | 46,589 | 34,077 | 37 |
| Inventory gain/(loss) | (2,521) | 469 | 2,193 | (638) | (215) | 539 | 1,271 | (58) |
| Reported EBITDA | 7,937 | 8,904 | 15,641 | (11) | (49) | 47,128 | 35,348 | 33 |
| Depreciation | (4,169) | (3,293) | (3,831) | 27 | 9 | (14,269) | (12,109) | 18 |
| Net income | 2,355 | 10,003 | 10,054 | (76) | (77) | 26,465 | 20,883 | 27 |
| Core Profit | 3,974 | 3,867 | 8,523 | 3 | (53) | 25,488 | 15,576 | 64 |
| EPS (Bt) | 0.42 | 1.79 | 1.80 | (76) | (77) | 4.74 | 3.98 | 19 |

Source: IVL, UOB Kay Hian

RESULTS

- Weak profit as expected.** Indorama Ventures (IVL) reported net profit of Bt2.4b in 4Q18 (-76% yoy, -77% qoq), dragged by lower margins and huge inventory loss of Bt2.5b. Excluding inventory loss, 4Q18 core profit would be Bt3.9b (+3% yoy, -53% qoq). Sales, EBITDA margin, core profit and net profit were in line with our expectations. 2018 core profit was Bt25b (+64% yoy).
- Key operational performances.** Although production volume hit a record high of 2.8m tons in 4Q18 (+22% yoy, +3% qoq), 4Q18 core EBITDA fell 38% yoy to US\$318m due to weaker blended margins for both PET and PTA, and unplanned shutdown of its facilities in Europe. PET margin fell sharply to US\$103/ton (3Q18: US\$154/ton) due to seasonality and resumed operations of PET plants in Asia. PTA margin fell 40% yoy to US\$56/tonne. IVL said there were unplanned shutdowns of its PTA plant in Netherlands and PET plant in Poland.

KEY FINANCIALS

| Year to 31 Dec (Btm) | 2017 | 2018 | 2019F | 2020F | 2021F |
|-------------------------------|---------|---------|---------|---------|---------|
| Net turnover | 286,332 | 347,171 | 373,253 | 419,930 | 422,661 |
| EBITDA | 30,818 | 43,350 | 56,482 | 63,329 | 70,948 |
| Operating profit | 18,579 | 29,077 | 38,482 | 44,329 | 49,448 |
| Net profit (rep./act.) | 20,883 | 26,465 | 28,483 | 31,815 | 35,734 |
| Net profit (adj.) | 15,576 | 25,488 | 28,483 | 31,815 | 35,734 |
| EPS (Bt) | 2.8 | 4.6 | 5.1 | 5.7 | 6.4 |
| PE (x) | 18.6 | 11.4 | 10.2 | 9.1 | 8.1 |
| P/B (x) | 2.5 | 2.0 | 1.7 | 1.5 | 1.3 |
| EV/EBITDA (x) | 13.6 | 9.6 | 7.4 | 6.6 | 5.9 |
| Dividend yield (%) | 1.9 | 2.0 | 2.2 | 2.3 | 2.4 |
| Net margin (%) | 7.3 | 7.6 | 7.6 | 7.6 | 8.5 |
| Net debt/(cash) to equity (%) | 75.7 | 90.2 | 70.9 | 56.8 | 41.7 |
| Interest cover (x) | 8.0 | 10.3 | 12.6 | 13.6 | 14.8 |
| ROE (%) | 20.3 | 20.2 | 17.8 | 17.0 | 16.7 |
| Consensus net profit | - | - | 28,123 | 29,386 | 31,409 |
| UOBKH/Consensus (x) | - | - | 1.01 | 1.08 | 1.14 |

Source: IVL, Bloomberg, UOB Kay Hian

BUY

(Maintained)

| | |
|--------------|---------|
| Share Price | Bt52.25 |
| Target Price | Bt77.00 |
| Upside | +48.1% |

COMPANY DESCRIPTION

PET and polyester fiber producer .

STOCK DATA

| | |
|---------------------------------|-----------|
| GICS sector | Materials |
| Bloomberg ticker: | IVL TB |
| Shares issued (m): | 5,614.6 |
| Market cap (Btm): | 291,956.7 |
| Market cap (US\$m): | 9,302.4 |
| 3-mth avg daily t'over (US\$m): | 33.7 |


Price Performance (%)

| | | | | |
|------------------|-----------------|-------------|------------|------------|
| 52-week high/low | Bt62.50/Bt45.00 | | | |
| 1mth | 3mth | 6mth | 1yr | YTD |
| 12.4 | (4.1) | (11.1) | (4.1) | (4.1) |

Major Shareholders

| | |
|--------------------------|-------|
| Lohia family | 66.0 |
| Bangkok Bank | 4.8 |
| FY19 NAV/Share (Bt) | 31.33 |
| FY19 Net Debt/Share (Bt) | 22.21 |

PRICE CHART



Source: Bloomberg

ANALYST(S)

Arsit Pamaranont
+662 659 8317
arsit@uobkayhian.co.th

STOCK IMPACT

- 2H18 dividend of Bt0.35/share.** The company announced a dividend of Bt0.35/share for 2H18. This implies a dividend yield of 0.6% based on current share price.
- Target doubling of EBITDA in 2023.** We attended IVL's yearly meeting yesterday. Group CEO Aloke Lohia briefed on the company's strategy over the next five years and provided updates on the long-term outlook for all its segments. The CEO targets to double EBITDA to US\$3.0b in 2023 (from US\$1.4b in 2018). IVL has reclassified its businesses into five new segments - integrated PET (combined PET and PTA businesses), olefins, fibers, packaging and specialty chemical.
- Focusing on M&A activities.** To achieve the EBITDA target, management guided capex of US\$4.5b in 2019-21, mainly for M&A in the packaging and specialty chemical segments which have higher EBITDA margins from high-value-add products (HVA). IVL also plans to spend almost US\$1.5b in capex over the next three years to improve efficiency of its ethylene cracker and set up new PET and PTA plants in the US.
- To continue to deliver impressive earnings growth in 2019.** Management reaffirms production volume growth of 25% to 13.0m tonnes in 2019, thanks to full-year contribution from acquisitions made last year. These include: a) 550,000-ton capacity from PET plants in Brazil; b) 540,000-ton PET plant in Egypt; and c) 700,000-ton production capacity from a PTA plant in Portugal. We also believe IVL will be able to keep its core EBITDA at US\$134/ton in 2019 (IVL sells 70% of its PET to Europe and the US on higher fixed contact margins). Thus, we believe IVL could achieve core EBITDA of US\$1.75b in 2019.

EARNINGS REVISION/RISK

- We maintain our 2019 core profit forecast of Bt28b.

VALUATION/RECOMMENDATION

- Maintain BUY and target price of Bt77.00,** based on 15x 2019F PE (its historical average after removing the abnormal impact from M&As in 2011-13). We foresee a high probability of consensus raising its 2019 earnings estimate. We think the market is overly concerned about the weaker performance continuing to 1Q19. However, IVL is trading at only 10x 2019F PE, the biggest discount historically, despite improving operational momentum.

SHARE PRICE CATALYST

- Rising PET spread.** About 40% of IVL's EBITDA comes from selling PET.

OPERATING STATISTICS -2018

| Year to 31 | 2018 | 2017 | yoy |
|---------------------------|--------|-------|-----|
| Production vol ('000 ton) | 10,419 | 9,103 | 14% |
| core EBITDA/ton | 138 | 110 | 25% |

Source: IVL

OPERATING STATISTICS -4Q18

| | 4Q18 | 4Q17 | 3Q18 | yoy % chg | qoq % chg |
|------------------------------|-------|-------|-------|-----------|-----------|
| Production volume ('000 ton) | 2,818 | 2,306 | 2,730 | 22 | 3 |
| core EBITDA (US\$/ton) | 113 | 111 | 150 | 2 | (25) |


Source: IVL

IVL TARGETS



Source: IVL, UOB Kay Hian

IVL FORWARD PE



Source: IVL, UOB Kay Hian

PROFIT & LOSS

| Year to 31 Dec (Btm) | 2018 | 2019F | 2020F | 2021F |
|----------------------------------|----------------|----------------|----------------|----------------|
| Net turnover | 347,171 | 373,253 | 419,930 | 422,661 |
| EBITDA | 43,350 | 56,482 | 63,329 | 70,948 |
| Deprec. & amort. | 14,273 | 18,000 | 19,000 | 21,500 |
| EBIT | 29,077 | 38,482 | 44,329 | 49,448 |
| Total other non-operating income | 2,786 | 750 | 800 | 800 |
| Associate contributions | 586 | 60 | 60 | 60 |
| Net interest income/(expense) | (4,227) | (4,490) | (4,673) | (4,800) |
| Pre-tax profit | 28,222 | 34,802 | 40,516 | 45,508 |
| Tax | (3,812) | (5,568) | (7,901) | (8,874) |
| Minorities | 128 | (750) | (800) | (900) |
| Net profit | 26,465 | 28,483 | 31,815 | 35,734 |
| Net profit (adj.) | 25,488 | 28,483 | 31,815 | 35,734 |

CASH FLOW

| Year to 31 Dec (Btm) | 2018 | 2019F | 2020F | 2021F |
|----------------------------------|-----------------|-----------------|-----------------|-----------------|
| Operating | 36,463 | 37,663 | 49,325 | 57,442 |
| Pre-tax profit | 28,222 | 34,802 | 40,516 | 45,508 |
| Tax | (3,812) | (5,568) | (7,901) | (8,874) |
| Deprec. & amort. | 14,273 | 18,000 | 19,000 | 21,500 |
| Working capital changes | (9,368) | (4,085) | (1,700) | 200 |
| Non-cash items | 2,056 | (750) | (800) | (900) |
| Other operating cashflows | 5,093 | (4,736) | 210 | 8 |
| Investing | (79,771) | (32,699) | (31,800) | (31,800) |
| Capex (growth) | (68,254) | (30,000) | (30,000) | (30,000) |
| Investments | (11,517) | (2,699) | (1,800) | (1,800) |
| Others | n.a. | n.a. | n.a. | n.a. |
| Financing | 42,009 | (4,522) | (14,980) | (19,759) |
| Dividend payments | (10,220) | (6,701) | (6,980) | (7,259) |
| Issue of shares | 16,103 | 0 | 0 | 0 |
| Proceeds from borrowings | 36,126 | 2,179 | (8,000) | (12,500) |
| Others/interest paid | n.a. | n.a. | n.a. | n.a. |
| Net cash inflow (outflow) | (1,299) | 442 | 2,545 | 5,883 |
| Beginning cash & cash equivalent | 6,877 | 5,578 | 6,021 | 8,566 |
| Ending cash & cash equivalent | 5,578 | 6,021 | 8,566 | 14,449 |

BALANCE SHEET

| Year to 31 Dec (Btm) | 2018 | 2019F | 2020F | 2021F |
|---------------------------------------|----------------|----------------|----------------|----------------|
| Fixed assets | 205,182 | 217,182 | 228,182 | 236,682 |
| Other LT assets | 49,728 | 52,900 | 54,900 | 57,000 |
| Cash/ST investment | 5,578 | 6,021 | 8,566 | 14,449 |
| Other current assets | 118,706 | 123,134 | 129,634 | 135,134 |
| Total assets | 379,195 | 399,237 | 421,282 | 443,265 |
| ST debt | 42,912 | 40,772 | 40,772 | 37,272 |
| Other current liabilities | 70,788 | 70,000 | 73,000 | 77,000 |
| LT debt | 93,244 | 89,244 | 81,244 | 72,244 |
| Other LT liabilities | 20,395 | 22,000 | 24,000 | 26,000 |
| Shareholders' equity | 144,838 | 174,939 | 199,774 | 228,250 |
| Minority interest | 7,018 | 2,282 | 2,492 | 2,500 |
| Total liabilities & equity | 379,195 | 399,237 | 421,282 | 443,266 |

KEY METRICS

| Year to 31 Dec (%) | 2018 | 2019F | 2020F | 2021F |
|---------------------------|------|-------|-------|-------|
| Profitability | | | | |
| EBITDA margin | 12.5 | 15.1 | 15.1 | 16.8 |
| Pre-tax margin | 8.1 | 9.3 | 9.6 | 10.8 |
| Net margin | 7.6 | 7.6 | 7.6 | 8.5 |
| ROA | 8.0 | 7.3 | 7.8 | 8.3 |
| ROE | 20.2 | 17.8 | 17.0 | 16.7 |
| Growth | | | | |
| Turnover | 21.2 | 7.5 | 12.5 | 0.7 |
| EBITDA | 40.7 | 30.3 | 12.1 | 12.0 |
| Pre-tax profit | 76.3 | 23.3 | 16.4 | 12.3 |
| Net profit | 26.7 | 7.6 | 11.7 | 12.3 |
| Net profit (adj.) | 63.6 | 11.8 | 11.7 | 12.3 |
| EPS | 63.6 | 11.8 | 11.7 | 12.3 |
| Leverage | | | | |
| Debt to total capital | 47.3 | 42.3 | 37.6 | 32.2 |
| Debt to equity | 94.0 | 74.3 | 61.1 | 48.0 |
| Net debt/(cash) to equity | 90.2 | 70.9 | 56.8 | 41.7 |
| Interest cover (x) | 10.3 | 12.6 | 13.6 | 14.8 |

Disclosures/Disclaimers

This report is prepared by UOB Kay Hian Private Limited ("UOBKH"), which is a holder of a capital markets services licence and an exempt financial adviser in Singapore.

This report is provided for information only and is not an offer or a solicitation to deal in securities or to enter into any legal relations, nor an advice or a recommendation with respect to such securities.

This report is prepared for general circulation. It does not have regard to the specific investment objectives, financial situation and the particular needs of any recipient hereof. Advice should be sought from a financial adviser regarding the suitability of the investment product, taking into account the specific investment objectives, financial situation or particular needs of any person in receipt of the recommendation, before the person makes a commitment to purchase the investment product.

This report is confidential. This report may not be published, circulated, reproduced or distributed in whole or in part by any recipient of this report to any other person without the prior written consent of UOBKH. This report is not directed to or intended for distribution to or use by any person or any entity who is a citizen or resident of or located in any locality, state, country or any other jurisdiction as UOBKH may determine in its absolute discretion, where the distribution, publication, availability or use of this report would be contrary to applicable law or would subject UOBKH and its connected persons (as defined in the Financial Advisers Act, Chapter 110 of Singapore) to any registration, licensing or other requirements within such jurisdiction.

The information or views in the report ("Information") has been obtained or derived from sources believed by UOBKH to be reliable. However, UOBKH makes no representation as to the accuracy or completeness of such sources or the Information and UOBKH accepts no liability whatsoever for any loss or damage arising from the use of or reliance on the Information. UOBKH and its connected persons may have issued other reports expressing views different from the Information and all views expressed in all reports of UOBKH and its connected persons are subject to change without notice. UOBKH reserves the right to act upon or use the Information at any time, including before its publication herein.

Except as otherwise indicated below, (1) UOBKH, its connected persons and its officers, employees and representatives may, to the extent permitted by law, transact with, perform or provide broking, underwriting, corporate finance-related or other services for or solicit business from, the subject corporation(s) referred to in this report; (2) UOBKH, its connected persons and its officers, employees and representatives may also, to the extent permitted by law, transact with, perform or provide broking or other services for or solicit business from, other persons in respect of dealings in the securities referred to in this report or other investments related thereto; (3) the officers, employees and representatives of UOBKH may also serve on the board of directors or in trustee positions with the subject corporation(s) referred to in this report. (All of the foregoing is hereafter referred to as the "Subject Business"); and (4) UOBKH may otherwise have an interest (including a proprietary interest) in the subject corporation(s) referred to in this report.

As of the date of this report, no analyst responsible for any of the content in this report has any proprietary position or material interest in the securities of the corporation(s) which are referred to in the content they respectively author or are otherwise responsible for.

IMPORTANT DISCLOSURES FOR U.S. PERSONS

This research report was prepared by UOBKH, a company authorized, as noted above, to engage in securities activities in Singapore. UOBKH is not a registered broker-dealer in the United States and, therefore, is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. This research report is provided for distribution by UOBKH (whether directly or through its US registered broker dealer affiliate named below) to "major U.S. institutional investors" in reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act"). All US persons that receive this document by way of distribution from or which they regard as being from UOBKH by their acceptance thereof represent and agree that they are a major institutional investor and understand the risks involved in executing transactions in securities.

Any U.S. recipient of this research report wishing to effect any transaction to buy or sell securities or related financial instruments based on the information provided in this research report should do so only through UOB Kay Hian (U.S.) Inc ("UOBKHUS"), a registered broker-dealer in the United States. Under no circumstances should any recipient of this research report effect any transaction to buy or sell securities or related financial instruments through UOBKH.

UOBKHUS accepts responsibility for the contents of this research report, subject to the terms set out below, to the extent that it is delivered to and intended to be received by a U.S. person other than a major U.S. institutional investor.

The analyst whose name appears in this research report is not registered or qualified as a research analyst with the Financial Industry Regulatory Authority ("FINRA") and may not be an associated person of UOBKHUS and, therefore, may not be subject to applicable restrictions under FINRA Rules on communications with a subject company, public appearances and trading securities held by a research analyst account.

Analyst Certification/Regulation AC

Each research analyst of UOBKH who produced this report hereby certifies that (1) the views expressed in this report accurately reflect his/her personal views about all of the subject corporation(s) and securities in this report; (2) the report was produced independently by him/her; (3) he/she does not carry out, whether for himself/herself or on behalf of UOBKH or any other person, any of the Subject Business involving any of the subject corporation(s) or securities referred to in this report; and (4) he/she has not received and will not receive any compensation that is directly or indirectly related or linked to the recommendations or views expressed in this report or to any sales, trading, dealing or corporate finance advisory services or transaction in respect of the securities in this report. However, the compensation received by each such research analyst is based upon various factors, including UOBKH's total revenues, a portion of which are generated from UOBKH's business of dealing in securities.

Reports are distributed in the respective countries by the respective entities and are subject to the additional restrictions listed in the following table.

| | |
|-----------------------------------|---|
| General | This report is not intended for distribution, publication to or use by any person or entity who is a citizen or resident of or located in any country or jurisdiction where the distribution, publication or use of this report would be contrary to applicable law or regulation. |
| Hong Kong | This report is distributed in Hong Kong by UOB Kay Hian (Hong Kong) Limited ("UOBKHHK"), which is regulated by the Securities and Futures Commission of Hong Kong. Neither the analyst(s) preparing this report nor his associate, has trading and financial interest and relevant relationship specified under Para. 16.4 of Code of Conduct in the listed corporation covered in this report. UOBKHHK does not have financial interests and business relationship specified under Para. 16.5 of Code of Conduct with the listed corporation covered in this report. Where the report is distributed in Hong Kong and contains research analyses or reports from a foreign research house, please note: (i) recipients of the analyses or reports are to contact UOBKHHK (and not the relevant foreign research house) in Hong Kong in respect of any matters arising from, or in connection with, the analysis or report; and (ii) to the extent that the analyses or reports are delivered to and intended to be received by any person in Hong Kong who is not a professional investor, or institutional investor, UOBKHHK accepts legal responsibility for the contents of the analyses or reports only to the extent required by law. |
| Indonesia | This report is distributed in Indonesia by PT UOB Kay Hian Sekuritas, which is regulated by Financial Services Authority of Indonesia ("OJK"). Where the report is distributed in Indonesia and contains research analyses or reports from a foreign research house, please note recipients of the analyses or reports are to contact PT UOBKH (and not the relevant foreign research house) in Indonesia in respect of any matters arising from, or in connection with, the analysis or report. |
| Malaysia | Where the report is distributed in Malaysia and contains research analyses or reports from a foreign research house, the recipients of the analyses or reports are to contact UOBKHM (and not the relevant foreign research house) in Malaysia, at +603-21471988, in respect of any matters arising from, or in connection with, the analysis or report as UOBKHM is the registered person under CMSA to distribute any research analyses in Malaysia. |
| Singapore | This report is distributed in Singapore by UOB Kay Hian Private Limited ("UOBKH"), which is a holder of a capital markets services licence and an exempt financial adviser regulated by the Monetary Authority of Singapore. Where the report is distributed in Singapore and contains research analyses or reports from a foreign research house, please note: (i) recipients of the analyses or reports are to contact UOBKH (and not the relevant foreign research house) in Singapore in respect of any matters arising from, or in connection with, the analysis or report; and (ii) to the extent that the analyses or reports are delivered to and intended to be received by any person in Singapore who is not an accredited investor, expert investor or institutional investor, UOBKH accepts legal responsibility for the contents of the analyses or reports only to the extent required by law. |
| Thailand | This report is distributed in Thailand by UOB Kay Hian Securities (Thailand) Public Company Limited, which is regulated by the Securities and Exchange Commission of Thailand. |
| United Kingdom | This report is being distributed in the UK by UOB Kay Hian (U.K.) Limited, which is an authorised person in the meaning of the Financial Services and Markets Act and is regulated by The Financial Conduct Authority. Research distributed in the UK is intended only for institutional clients. |
| United States of America ('U.S.') | This report cannot be distributed into the U.S. or to any U.S. person or entity except in compliance with applicable U.S. laws and regulations. It is being distributed in the U.S. by UOB Kay Hian (US) Inc, which accepts responsibility for its contents. Any U.S. person or entity receiving this report and wishing to effect transactions in any securities referred to in the report should contact UOB Kay Hian (US) Inc. directly. |

Copyright 2019, UOB Kay Hian Pte Ltd. All rights reserved.

<http://research.uobkayhian.com>

RCB Regn. No. 197000447W